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Abstract
RNA binding proteins (RBPs) and microRNAs (miRNAs) are two of the most important post-transcriptional regulators
of gene expression, and their aberrant expression contributes to the development of human malignancies. Let-7,
one of the most well-known tumor suppressors, is frequently down-regulated in a variety of human cancers. The
RBP LIN28A/LIN28B, a direct target of the let-7 family of miRNAs, is an inhibitor of let-7 biogenesis and is frequently
up-regulated in cancers. Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors is
reportedly involved in cancer development, contributing to cellular proliferation, cell death resistance, angiogenesis,
metastasis, metabolism reprogramming, tumor-associated inflammation, genome instability, acquiring immortality
and evading immune destruction. In this review, we summarized the mechanisms of LIN28A/LIN28B and let-7 loop
aberrant regulation in human cancer and discussed the roles and potential mechanisms of the LIN28A/LIN28B and
let-7 loop in regulating the hallmarks of cancer. The crosstalk between LIN28A/LIN28B and let-7 loop and certain
oncogenes (such as MYC, RAS, PI3K/AKT, NF-κB and β-catenin) in regulating hallmarks of cancer has also been discussed.
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A double-negative feedback loop between
LIN28A/LIN28B and let-7
MicroRNAs (miRNAs) are small non-coding RNAs that
bind the mRNA of target genes to inhibit their translation
and/or induce their decay. MicroRNAs thus play a crucial
role in many biological events, including tumorigenesis.
Briefly, most miRNAs are transcribed by RNA polymerase
II [1]. Primary miRNA transcripts (pri-miRNAs) are then
processed in the nucleus by the RNAseIII Drosha into
70-100-nt-long pre-miRNAs, which are then exported
to the cytoplasm and cleaved by the RNAse III Dicer to
form ~22-nt-long dsRNAs (miRNA). Finally, the RNA-
induced silencing complex (RISC) binds to one strand
of the dsRNA and guides it to target mRNA for subse-
quent silencing [2].
The miRNA let-7 was identified in the nematode Cae-
norhabditis elegans in 2001, seven years after let-4, the
first known miRNA, was identified in the same species
[3]. The let-7 family of miRNAs is the largest of all
miRNA families, and members of this family are highly
conserved in sequence and function from C. elegans to
humans [4, 5]. It’s now known that members of let-7
family play important roles in regulating cellular differ-
entiation, metabolism and the development of certain
diseases, including tumorigenesis [6].
The highly conserved RNA binding proteinLIN28
family includes two homologous members, LIN28A and
LIN28B, each having similar domain structure and func-
tion. Like let-4 and let-7, LIN28A was also first identified
in C.elegans [7], though it is also present in a wide var-
iety of mammals. Notably, LIN28A gene mutation in C.
elegans results in disturbance of its developmental
timing [8]. LIN28B was first identified in hepatocellular
carcinoma, where levels of the protein were high [9]. Re-
cent studies found that LIN28A/LIN28Band let-7 family
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miRNAs tend to have opposing roles in many cellular
processes, in particular those involved in cancer devel-
opment and progression [10]. Indeed, LIN28A/LIN28B
and let-7 are inversely expressed in normal and malig-
nant tissues [11, 12]. The presence of a double-negative
feedback loop between LIN28A/LIN28B and let-7 was
also reported [10].
LIN28A/LIN28B negatively regulates let-7family miR-
NAs via its RNA-binding domains (RBDs), which in-
clude a cold-shock domain (CSD) at the N-terminus and
two Cys-Cys-His-Cys (CCHC)-type zinc finger domains
at the C-terminus [13–16]. Both the CSD and CCHC
zinc fingers of LIN28A/LIN28B can interact with the
conserved residues ofpri-let-7 and pre-let-7. Briefly, the
CSD inserts into the apical point of the precursor loop,
while the CCHC zinc fingers dimerize on a GGAG motif
adjacent to the Dicer cleavage site [17, 18]. The binding
of LIN28A/LIN28B to either pri-let-7 or pre-let-7 in-
hibits let-7 precursor processing by Drosha and Dicer
[19]. Upon binding to pre-let-7, LIN28A/LIN28B re-
cruits TUT4/TUT7, which causes oligo-uridylation at
the 3′terminal of pre-let-7 [20–22]. Under normal con-
ditions, Dicer recognizes the two-nucleotides at the 3′
terminal via its PAZ domain; however, oligo-uridylation
elongates the 3′ terminal resulting in resistance to Dicer
cleavage. Oligo-uridylated pre-let-7 can also be degener-
ated by the 3′-5′ exonuclease Dis312 [23, 24]. Thus,
LIN28A/LIN28B not only inhibits the biogenesis of let-7
family miRNAs, but also induces their degradation. Con-
versely, let-7 miRNA may bind complementary sites on the
3′ UTR of both LIN28A and LIN28B mRNAs, thus inhi-
biting the expression and function of LIN28A/LIN28B
protein [9, 25]. This double-negative feedback loop
between LIN28A/LIN28B and let-7 is shown in Fig. 1.
The mechanisms of aberrant expression of
LIN28A/LIN28B and let-7 in cancer
LIN28A/LIN28B proteins are frequently up-regulated in
various malignancies originating from three germ layers
(Table 1). High levels of LIN28A/LIN28B proteins are
associated with many cancer biological behaviors and
poor prognosis.
LIN28A/LIN28B transactivation by various transcription
factors in malignancies has been extensively studied.
LIN28B may be up-regulated via direct promoter binding
by the transcription factor c-myc upon activation of the
MAPK signaling pathway [26] or by NF-κB during inflam-
mation [27]. LIN28B may also be up-regulated by STAT3
during inflammation-mediated epithelial-to-mesenchymal
transition (EMT) [28] or by β-catenin upon activation of
the Wnt signaling pathway [29]. The transcriptional factor
SOX2 reportedly up-regulates LIN28A by binding to a
proximal site on the promoter and facilitating promoter
acetylation via interaction with the histone acetyl-
transferase complex [30].
LIN28A/LIN28B is also regulated post-transcriptionally.
In addition to let-7, the miRNAs miR-26a, miR-181, miR-9,
miR-30, miR-125, miR-212 and miR-27 have also been
shown to directly bind the 3′UTR of LIN28A/LIN28B and
repress translation of the protein, and as these miRNAs are
frequently under-expressed in malignant tumors, higher
levels of LIN28 expression are seen [31–34]. Notably, a
potential regulatory loop reportedly exists between LIN28B
and miR-212 in androgen-independent prostate cancer
Fig. 1 A double-negative feedback loop between LIN28A/LIN28B and let-7
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[35]. A recent study revealed that LIN28A/LIN28B mRNA
contains an AU-rich element (ARE) within its 3′UTR, and
the tumor suppressor tristetraprolin (TTP), an ARE bind-
ing protein, enhances the degradation of LIN28A/LIN28B
mRNA; however, TTP is often repressed in human cancers,
which may also contribute to the elevation of LIN28A/
LIN28B in certain cancer types [36]. The ribonuclease
DIS3, one of the most frequently mutated genes in multiple
myeloma, is an inhibitor of LIN28B through binding and
degrading LIN28B mRNA [37]. More recent research
revealed that the expression of insulin-like growth factor 2
(IGF2) mRNA-binding protein 3 (IMP3), a protein which
regulates RNA localization, translation and stability, corre-
lates with that of LIN28B and cytoplasmic IMP3 granules
contain LIN28B mRNA. Further studies showed that IMP3
recruits LIN28B mRNA and prevents the binding of
argonaute 2 (Ago2) and let-7 to LIN28B, thus allowing the
increased expression of it and other let-7 target genes, like
HMGA2 [38]. Additionally, the protein level of LIN28B
has been revealed to be regulated via ubiquitin-mediated
proteasomal degradation. The human TRIM-NHL domain-
containing protein TRIM71, an ubiquitin ligase, was
reported to negatively regulate the stability of LIN28B
protein by catalyzing its polyubiquitination [39].
However, weather the regulation of LIN28B protein is
altered in malignancies is still waiting for further ex-
periments to reveal.
In contrast to the expression of LIN28A/LIN28B pro-
teins, the expression of let-7 family miRNAs is typical
decreased in cancers (Table 1). While let-7 miRNAs may
be regulated at multiple levels, most studies support the
significance of their post-transcriptional regulation. For
instance, during tumorigenesis, mature let-7 was found
to be absent, whereas pri-let-7 was present at high levels,
which suggests post-transcriptional regulation of mature
let-7 [40]. As previously mentioned, LIN28A/LIN28B is
a common post-transcriptional repressor of let-7 miR-
NAs. In addition to LIN28A/LIN28B proteins, the com-
plex of NF90 and NF45 proteins can inhibit pri-let-7a
processing into pre-let-7a by binding to pri-let-7a [41],
while Ago proteins can bind and stabilize mature
miRNAs and thereby increase let-7 levels [42]. Import-
antly, as the endonucleases Drosha and Dicer are essen-
tial for the processing of miRNA to maturation, factors
Table 1 Pathological associations of increased LIN28A/LIN28B and or of decreased let-7 expression in various cancer tissues
Origin Cancer type Ref. Pathological association
Endoderm Colon LIN28↑ [12, 74] Increased tumor progression and metastasis
Let-7↓ [113, 114] Poor prognosis
Lung LIN28↑ [12, 115] Increased proliferation
Let-7↓ [116] Poor prognosis; increased cellular proliferation
Hepatocellular carcinoma LIN28↑ [12, 117] Advanced-stage cancer
Let-7↓ [118] Metastatic cancer; increased proliferation and migration
Gastric adenocarcinoma LIN28↑ [119] Poor prognosis
Let-7↓ [76] Increased invasion and metastasis
Esophageal LIN28↑ [75] Increased proliferation and metastasis
Pancreatic Let-7↓ [120] Increased proliferation
Mesoderm Cervical LIN28↑ [12]
Ovarian LIN28↑ [12, 121] High-grade cancer
Let-7↓ [121, 122] High-grade cancer
Germ cell tumor LIN28↑ [123] Poor prognosis
Prostate LIN28↑ [124] Increased proliferation
Let-7↓ [125] Increased proliferation
Chronic myeloid leukemia LIN28↑ [12] Increased tumor progression
Burkitt lymphoma Let-7↓ [126, 127] Increased proliferation
Renal cell carcinoma Let-7↓ [128] Metastatic and high-grade cancer
Ectoderm Breast LIN28↑ [12, 55, 129] Increased tumor aggressiveness and proliferation
Let-7↓ [81] Lymph node metastasis
Oral squamous cell carcinoma LIN28↑ [90] Poor prognosis
Glioma LIN28↑ [130] Increased proliferation
Melanoma Let-7↓ [131] Increased invasion
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influencing the activity or expression of these endonu-
cleases impact the processing of miRNAs. For instance,
Fas and TRAIL-R2 were reported to reduce the levels of
mature let-7 miRNA by inhibiting the activities of Dicer
[43] and Drosha [44], respectively.
Regulation of let-7 expression also occurs at the tran-
scriptional level. Notably, the presence of a CpG island
in the promoter region of let-7a-3, located on chromo-
some 22q13.31, allows for epigenetic regulation via DNA
methyltransferases DNMT1 and DNMT3B [45, 46]. The
nuclear hormone receptor DAF-12, a transcriptional ac-
tivator or repressor depending on the presence or ab-
sence of a DA (dafachronic acid) ligand, can directly
modulate the transcription of certain let-7 miRNAs [47].
Conversely, let-7 miRNAs can repress DAF-12 expres-
sion by binding its 3′UTR, which suggests a complex
feedback loop between DAF-12 and let-7 miRNAs [48].
In addition to being repressed for their expression, the
antitumor functions of let-7 have also been attenuated in
malignant tumor cells. Competing endogenous RNA
(ceRNA) is a hypothesis driven by the reasoning that
mRNA, transcribed pseudogenes and long non-coding
RNA (lncRNA) compete for a limited pool of miRNAs
[49]. Even though the hypothesis of ceRNA is challenged
by some researchers recently [50], ceRNAs attenuating
let-7-mediatedantitumor activity has been extensively re-
ported. For example, the lncRNAH19 reportedly inhibits
the bioavailability of let-7 family miRNAs through a
molecular sponge mechanism [51]. A recent study also
found that high-mobility group A (HMGA2), a non-
canonical transcriptional factor, promoted lung cancer
progression independent of its protein-coding func-
tion. Indeed, HMGA2 functions as a ceRNA, compet-
ing with the transforming growth factor beta receptor
3(TGFBR3) for let-7, thus allowing for the heightened
expression of TGFBR3 and subsequent lung cancer
progression [52].
As discussed, the expression patterns and functions of
LIN28A/LIN28B and let-7 in malignancies are largely
opposing and appear to compose a double-negative feed-
back loop regulating cancer progression.
LIN28A/LIN28B and let-7 loop regulates the
hallmarks of cancer
Hanahan and Weinberg famously described ten biological
capabilities acquired by cancer during development [53].
These include: sustaining proliferative signaling, resisting
cell death, evading growth suppressors, inducing angiogen-
esis, enabling replicative immortality, activating invasion
and metastasis, accumulating genome instability, inducing
inflammation, reprogramming of energy metabolism and
evading immune destruction [53]. To date, the LIN28A/
LIN28B and let-7 loop has been demonstrated to regulate
almost all of these hallmarks.
LIN28A/LIN28B and let-7 loop regulates cancer cell
proliferation
One of the most fundamental characteristics of cancer
cells is their capacity for uncontrolled proliferation. Unlike
normal cells, whose proliferation is strictly controlled to
maintain homeostasis, cancer cells have developed the
ability to sustain proliferative signaling, therein becoming
masters of their own destinies [53]. Many studies of
multiple cancer types have shown that LIN28A/LIN28B
promotes the proliferation of cancer cells through five
different mechanisms: up-regulation of cell cycle regula-
tors, elevation of cellular proliferative signaling, activation
of proliferation-associated transcription factors, facilita-
tion of ribosomal protein synthesis and activation of cellu-
lar metabolism.
LIN28A/LIN28B has been demonstrated to up-regulate
cell-cycle regulators in two ways. First, LIN28A/LIN28B
directly binds and promotes the translation of numerous
mRNAs encoding cyclins (cyclinA, cyclinB and cyclinD),
cyclin-dependent kinases (CDK1, CDK2 and CDK4) and
cell division cycle proteins (CDC2 and CDC20) [54].
Secondly, through repressing let-7, LIN28A/LIN28B indir-
ectly up-regulates some cell-cycle regulators targeted by
let-7, such as cyclinD1/2, CDK6, CDC34, CDC25a and
Trim71 (a repressor of CDK inhibitor 1A).
LIN28A/LIN28B can elevate cellular proliferation sig-
nals in both let-7-dependent and -independent manners.
Through inhibiting let-7, LIN28A/LIN28B can activate a
variety of cellular proliferation signaling pathways. For
instance, let-7 targets the IGF1 receptor and AKT2 to
inhibit PI3K/AKT pathway activity and RAS to inhibit
MAPK pathway activity. Thus, inhibition of let-7 by
LIN28A/LIN28B would increase the activities of both
pathways and, subsequently, increase proliferation. As a
RNA binding protein, LIN28A/LIN28B also directly binds
to and promotes the translation of IGF2. Recently, it was
also found that LIN28A/LIN28B promotes the expression
of human epidermal growth factor receptor 2 (HER2) at
the post-transcriptional level in breast cancer cells [55].
Activation of transcriptional factors necessary for cel-
lular proliferation in a let-7-dependent manner is an-
other method by which LIN28A/LIN28B can increase
proliferation. For instance, hepatitis B virus x protein
(HBx) promotes cellular proliferation through down-
regulating let-7 expression, thus elevating levels of the
transcription factor signal transducer and activator of
transcription 3 (STAT3), another let-7 target, in HBV in-
fected cells [56]. Additionally, let-7 represses the prolif-
eration of cancer cells by directly targeting HMGA2, a
protein which is frequently over-expressed in and pro-
motes proliferation of many cancer types [52, 57, 58].
LIN28A can also increase cellular proliferation through
directly binding to and promoting the translation of nu-
merous mRNAs encoding ribosomal proteins, such as
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RPS13, EEF1G and EIF4A [59]. Additionally, through the
LIN28A/LIN28B-mediated inhibition of let-7, PI3K/AKT-
mTOR signaling may promote ribosomal biogenesis and
translation in mammary cells via activating S6, eIF4E and
eIF4B, as let-7 is known to target key components of this
pathway, such as AKT2 and Raptor [60, 61]. A detailed
discussion of the LIN28A/LIN28B-mediated activation of
cellular metabolism and subsequent promotion of cellular
proliferation is presented in the next section.
Of note, under certain conditions, LIN28A/LIN28B
may also inhibit cancer cell proliferation. Indeed, Song
et al. reported that over-expression of LIN28A/LIN28B
in gastric cancer cell line BGC-823 inhibited prolifera-
tion through some unknown mechanism [62]. However,
as the authors used only one cell line, whether LIN28A/
LIN28Btruly inhibits proliferation of gastric cancer cells
is still not clear. Moreover, since extensive elevation of
oncoproteins, such as RAS, MYC and RAF, can induce
cell senescence and/or apoptosis [53], the reported
inhibition may have been the result of cell senescence
triggered by extensive proliferative signals.
LIN28A/LIN28B and let-7 loop regulates cancer cell
metabolism
Metabolic shift is a basic property of cancer cells. In the
1920s, Otto Warburg discovered that glycolysis was main-
tained in cancer cells in conditions of high oxygen tension,
otherwise known as “aerobic glycolysis”. During enhanced
glucose uptake and elevated glycolysis, intermediates of the
glycolytic pathway become a major resource for anabolic
reactions in cancer cells. For example, dihydroxyacetone
phosphate is important for synthesis of triacylglycerides
and phospholipids, glucose 6-phosphate is necessary for
the synthesis of glycogen and ribose 5-phosphate, and
pyruvate is an important progenitor of amino acids and
may enter a truncated tricarboxylic acid (TCA) cycle and
generate acetyl-CoA, which is necessary for the synthesis
of fatty acids, cholesterol and isoprenoids. Thus, through
augmenting anabolic reactions, glycolysis is a promoter of
cancer cell growth and proliferation [63]. Both LIN28A
and LIN28B reportedly enhance aerobic glycolysis, while
let-7 suppresses this process at least in part through tar-
geting pyruvate dehydrogenase kinase 1(PDK1), which
negatively regulates pyruvate dehydrogenase (PDH), thus
preventing pyruvate entry into TCA under normoxic
conditions [64]. LIN28A/LIN28B also directly potenti-
ates cellular metabolism through binding and regulating
translation of glycolysis enzymes such as hexokinase 1
(HK1), pyruvate dehydrogenase alpha 1 (PDHA1) and
PDHB [59].
Insulin signaling is a master regulator of cellular ana-
bolic metabolism [65]. By activing the PI3K/AKT path-
way through binding insulin receptors, insulin not only
facilitates glucose uptake and promotes glycogenesis, but
also promotes protein synthesis and lipogenesis. Thus,
insulin-PI3K/AKT signaling is a key regulator coupling
cellular anabolic metabolism with cellular growth and
proliferation. Through let-7, LIN28A/LIN28B activates
insulin signaling by elevating components involved in in-
sulin signaling pathways, such as IGF1R, insulin receptor
(InsR), IRS2, AKT2 and Rictor (Fig. 2) [60]. LIN28A/
LIN28Balso directly activates insulin signaling through
binding and activating translation of components and
regulators of insulin signaling pathways, such asIGF2
and HMGA1. IGF2 is a ligand of InsR, and the inter-
action between IGF2 and InsR triggers the activation of
Fig. 2 Let-7 targets insulin signaling pathway and thus inhibits cancer cell metabolism
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insulin signaling. HMGA1 is a key regulator of the tran-
scription of InsR [66].
LIN28A/LIN28B and let-7 loop mediates cancer cell evasion
of immune destruction
The immune system is responsible for recognizing and
eliminating cancer cells; however, tumors typically evade
immune destruction through either avoiding detection
by the immune system or limiting the extent of im-
munological eradication [53]. Recent studies suggest that
the LIN28A/LIN28B and let-7 loop may also regulate
cancer cell immune evasion.
The transmembrane protein Fas (CD95) is a member
of the tumor necrosis factor (TNF) receptor superfamily.
Binding of either Fas ligand (Fas-L), a type II transmem-
brane protein expressed on cytotoxic T lymphocytes, or
TNFα, a cytokine secreted by activated macrophages
and other immune cells, induces trimerization of Fas in
the membrane of the target cell (including cancer cells)
and results in the activation of Fas. Fas activation then
leads to the activation of caspase 8, triggering extrinsic
apoptosis [67]. Let-7 expression has been shown to de-
crease during Fas-mediated apoptosis because Fas acti-
vation suppresses Dicer; however, exogenous expression
of let-7 inhibits cell sensitivity to Fas-mediated apop-
tosis via directly targeting Fas [43, 68], which suggests
that let-7 family miRNAs may suppress tumor innate
immune reactions.
Toll-like receptors (TLRs) are a class of transmem-
brane proteins expressed in macrophages, neutro-
phils, dendritic cells and other immune cells, and
play a key role in innate immune response via recog-
nizing inflammatory mediators, costimulatory mole-
cules and even conserved structures of microbes.
Peptides, lipopolysaccharides and nucleic acids may
each act as TLR ligands [69]. TLRs are universally
expressed in many cancer types and promote the de-
velopment of inflammation-associated malignances
through activating the inflammatory response. How-
ever, TLRs have also been shown to be sensors of
cell death, and stimulation of TLRs to activate the
innate immune system is a strategy currently under
development for cancer therapy [69]. A recent study
uncovered that extracellular let-7 interacts with and
then activates TLR7, an RNA-sensing neuronal TLR,
and induces neurodegeneration [70]. Interestingly, in
a metastatic gastric cancer cell line, let-7 family miR-
NAs could be selectively secreted into the extracellu-
lar environment via exosomes [71]. These results
suggest that the activation of TLR7 induced by
extracellular let-7 may also be involved in the regu-
lation of immune response or inflammation in can-
cer; however, this hypothesis has yet to be validated
experimentally.
LIN28A/LIN28B and let-7 loop mediates tumor-associated
inflammation
Inflammation is linked clinically and epidemiologically
to cancer. However, the molecular intersections between
inflammation and cancer progression have been unclear
for a long time. Recently, it was demonstrated that the
LIN28A/LIN28B and let-7 loop is a key switch linking
inflammation to cell transformation. Viswanathan et al.
were the first to evaluate the role of LIN28A in cell
transformation, over-expressing LIN28A in NIH/3 T3
cells [12]. They observed that LIN28A over-expression
promoted 3 T3 cells to form clones in vitro and form
solid tumors in nude mice with a concomitant down-
regulation of multiple mature let-7 family member miR-
NAs. Importantly, this effect could be attenuated by re-
introducing let-7. Recently, a consistent result was ob-
served by Madison et al. in intestinal epithelial cells.
They showed that targeted expression of LIN28B pro-
moted crypt transformation and fostered intestinal polyp
and adenocarcinoma formation in vivo in a let-7-
dependent manner [72]. In revisiting the molecular
intersection between inflammation and cancer progres-
sion, Dimitrios and colleagues revealed such an intersec-
tion between inflammation and cell transformation [27].
They showed that over-expression of LIN28B upon the
activation of NF-κB inhibited the generation of let-7
family member miRNAs and elevated the production of
IL-6, a target of let-7. In turn, IL-6 activated NF-κB and
STAT3 transcription factors through the RTK signaling
pathway. The activation of NF-κB and subsequent produc-
tion of IL-6 thus formed a positive feedback loop (Fig. 3),
while STAT3 activation is necessary for the transformation
of normal cells. Furthermore, they showed that STAT3
directly activated miR-181b and miR-21 at the transcrip-
tional level. MiR-181b and miR-21 target cylindromatosis
(CYLD) and phosphatase and tensin homolog (PTEN),
respectively, and down-regulation of CYLD and PTEN
leads to NF-κB activation, therefore also acting as a part of
the epigenetic switch linking inflammation to cancer [73]. As
previously mentioned, STAT3 also suppresses the expression
of let-7 through directly activating LIN28A/LIN28B expres-
sion during inflammation-stimulated EMT [28].
LIN28A/LIN28B and let-7 loop regulates metastasis
Local invasion and distant metastasis are marks of
higher pathological stages of malignant cancers. While
the invasion-metastasis cascade is known to consist of a
succession of processes, beginning with local invasion and
followed by intravasation (cancer cell invasion into blood
and lymphatic vessels) and extravasation (cancer cell escape
from vessels) to form micrometastases and finally grow into
macroscopic tumors, the mechanisms involved in this
multistep process are still being defined. Of all the steps,
however, local invasion is the most extensively studied.
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EMT is broadly believed to regulate invasion [53].
EMT is characterized as epithelial cells losing their cell
polarity and cell-cell adhesion with the loss of E-
cadherin expression usually driven by the elevated ex-
pression of a set of transcriptional factors, such as Snail,
Slug, Twist and Zeb1/2 [53]. Involvement of the
LIN28A/LIN28B and let-7 loop in the regulation of can-
cer cell invasion and metastasis is, naturally, intimately
associated with EMT. Many studies have shown that
LIN28A/LIN28B promotes and let-7 inhibits invasion
and metastasis in various cancer types, including colon
cancer, breast cancer, hepatocellular carcinoma, pancre-
atic cancer, gastric cancer, lung cancer and esophageal
cancer [57, 74–79]. In fact, the mechanism by which
let-7 inhibits invasion and metastasis is, actually, well-
studied. HMGA2 is the most frequently reported target
of let-7 in the process of inhibiting invasion and metas-
tasis [57, 77]. HMGA2 has been demonstrated to pro-
mote EMT by inducing the expression of Slug and Snail
and then inhibiting the expression of E-cadherin in
many cancer types [57, 80]. In addition to regulating
invasion and metastasis via a coding gene, HMGA2 also
functions as a ceRNA to facilitate cancer metastasis in
certain cancer types [52]. As previously mentioned, by
competing with TGFBR3 to bind let-7, HMGA2 re-
presses the inhibitory effect of let-7 on TGFBR3, thus
elevating TGFBR3protein and facilitating cancer inva-
sion and metastasis [52]. BesidesHMGA2, let-7 also was
reported to inhibit invasion, migration and metastasis
via targetingITGB3, MAP4K3 and MYH9 [76, 79]. A re-
cent study showed that let-7 inhibited the cancer cell
migration via direct targeting of four genes in the actin
cytoskeletal pathway, including RDX, DIAPH2, ITGB8
and PAK1 [81]. IL-6 was also a direct target of let-7 to
inhibit cancer cell invasion and migration. It was re-
ported that down-regulation oflet-7 in cancer-associated
mesenchymal stem cells (MSCs) results in the enhanced
secretion of IL-6, and IL-6 then promotes prostate cancer
cell metastasis [82]. LIN28A/LIN28B promotes invasion
and metastasis through the let-7/HMGA2/Slug or Snail/E-
cadherin axis [57, 77], but also in a let-7-independent man-
ner. LIN28A directly binds and promotes the translation
Fig. 3 A positive feedback between LIN28A/LIN28B and transcriptional factor NF-κB and STAT3 in the process of inflammation mediated
cancer progression
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of HMGA1, and like HMGA2, HMGA1 promotes EMT
by inducing the expression of Slug and Snail. Additionally,
LIN28A has been found to directly bind E-cadherin
mRNA and repress the translation of E-cadherin mRNA
in embryo stem cells [83]; however, the role of LIN28Ain
directly regulating E-cadherin expression in cancer cells is
still unclear.
LIN28A/LIN28B and let-7 loop regulates cancer cell death
The LIN28A/LIN28B and let-7 axis is known to regulate
cellular apoptosis and is involved in resistance/sensitiv-
ity to therapy. Many studies have shown that the over-
expression of let-7 or knockdown of LIN28A/LIN28B
increases the radiosensitivity or chemosensitivity of
cancer cells [84–87]. Let-7 reportedly induces cellular
apoptosis through targeting the anti-apoptotic protein
B-cell lymphoma-extra large (BCL-XL) in many cell
types [86–88] as well as the IL-6/STAT3 pro-survival
pathway [89]. While LIN28A/LIN28B represses apop-
tosis via let-7, it may also regulate the expression of
pro-apoptosis and/or anti-apoptosis genes through un-
identified mechanisms. For example, over-expression of
LIN28B in oral cancer cells promotes the expression of
Survivin, an apoptosis inhibitor [90].
Recently, the existence of a subclass of neoplastic cells,
termed cancer stem cells (CSCs), in many tumors is
thought to be the root cause of chemotherapeutic failure
and tumor recurrence because CSCs are resistant to
apoptosis [53]. While the LIN28A/LIN28B and let-7
loop is known to be involved in the development of che-
motherapeutic sensitivity of cancer cells to apoptosis, it
is also purportedly involved in the maintenance and/or
differentiation of CSCs. Firstly, in many cancer types,
high levels of LIN28A and other stem cell maintenance
factors, such as OCT4, are present in a sub-population
of cells with CSC properties [91–93]. Secondly, forced
expression of LIN28A promotes the expression of CSC
markers as well as the self-renewal capability of CSCs,
while knock-down has the opposite effect [74, 92].
Lastly, through the down-regulation of let-7, enhanced
expression of LIN28A induced the development of CSC
‘stemness’ coupled with resistance to chemotherapy-
induced apoptosis [94, 95].
Of note, let-7 may inhibit apoptosis under certain con-
ditions. For example, forced let-7a expression in A431
and HepG2 cells increased resistance to apoptosis in-
duced by doxorubicin and paclitaxel through the direct
targeting of caspase-3 [96]. Additionally, up-regulation
of let-7 family miRNA expression upon estrogen expos-
ure in endometrial adenocarcinoma enhanced cellular
survival through the direct targeting of the anti-apoptosis
gene BAX [97]. These results suggest that the let-7 family
miRNAs play a multifaceted role in the regulation of
cellular apoptosis.
LIN28A/LIN28B and let-7 loop regulates genome instability
In normal cells, the stability and integrity of the genome
is maintained by a functional DNA damage repair
system. However, in cancer cells, this system is often de-
fective resulting in genome instability and the acceler-
ated accumulation of mutations. While these effects are
typically necessary for and contribute to cancer progres-
sion, certain mutations may also be deadly for cancer
cells or increase their sensitivity to various therapeutic
modalities [53]. In radiation-treated cancer cells, LIN28A/
LIN28B over-expression reportedly inhibits the expression
of gamma-H2AX, which is an activate form of histone
H2AX and is necessary for repair of double strand breaks
(DSBs) [98], which suggests that LIN28A/LIN28B may in-
crease genome instability by inhibiting DSB repair [85].
However, a recent study found that the expression of let-7
was decreased in colon cancer cells following radiation
exposure [99]. Another study showed that p53 directly
bound to and inhibited the expression of let-7 during this
process [99]. Moreover, the exogenous expression of let-7
increased radiation-induced cytotoxicity, which suggests
that let-7 family miRNAs may also increase the genome-
instability of cancer cells.
LIN28A/LIN28B and let-7 loop may regulate other
hallmarks of cancer
Angiogenesis is required for tumors to survive as they
need a steady supply of nutrients and oxygen as well as
a means of evacuating metabolic waste. The most
thoroughly-studied inducer of angiogenesis is vascular
endothelial growth factor (VEGF). A recent study showed
that stable expression of LIN28B in oral cancer cells pro-
moted the expression of VEGF, suggesting that LIN28A/
LIN28B may be involved in the regulation of tumor
angiogenesis [90].
To generate macroscopic tumors, cancer cells also have
to acquire the capability of replicative immortality, partially
through conquering senescence, a barrier to proliferation
and characterized as irreversible entrance into a non-
proliferative but viable state [53]. Cellular senescence in-
volves transcriptional repression of proliferation-promoting
genes mediated by the retinoblastoma (RB1)/E2F tran-
scriptional repressor complex. Interestingly, let-7 report-
edly triggers human cell senescence through modifying
chromatin at the promoters of RB1/E2F target genes,
thus repressing their transcription, which suggests that
the LIN28A/LIN28B and let-7 loop may also be in-
volved in the regulation of cancer cellular replicative
immortality [100].
Crosstalk between LIN28/let-7 loop and oncogenes in
regulating hallmarks of cancer
Transcription factor myc is a well-established oncogene.
More than 70 % of all tumors have some form of c-MYC
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gene dysregulation [101]. It has been well-known that
myc controls the proliferation of cancer cells. Recently,
it has also been shown that myc regulates the metabol-
ism, cancer related inflammation, metastasis, angio-
genesis, and genome instability of malignancies. Thus, myc
is a master regulator to control the progression of malig-
nancies via mediating crosstalk of hallmarks of cancer.
The function of myc in regulating the proliferation of
cancer cells has been well-documented. Myc directly
transactivates most of the critical positive cell cycle reg-
ulators (such as Cdks and cyclins) but block the tran-
scription of cell cycle inhibitors (such as p21). Moreover,
myc directly promotes DNA replication by facilitating
the replication initiation and hyperactivatescyclin/Cdk
complexes via activation of Cdc25 phosphatases and
Cdk activating kinase (CAK) [102]. In addition to regu-
late proliferation, the myc oncogene was shown to en-
hance glycolysis and alter amino acid metabolism in
cancer cells [103]. Myc is known to directly activate the
expression of almost all genes encoding glycolytic en-
zymes, such as lactate dehydrogenase (LDH), hexokinase
2 and enolase 1. Also, myc enhances glucose uptake via
activating the expression of the glucose transporter
GLUT1 [103, 104]. Besides glucose, cancer cells also take
up and use glutamine to accumulate biomass. Glutamine
is converted into glutamate by glutaminase (GLS), and
glutamate drives the biogenesis of acetyl-CoA through a
reverse TCA cycle. Myc promotes glutaminolysis and
the generation of glutamate through activating the ex-
pression of GLS. As previously states, the activation of
tumor associated macrophage (M2 type macrophage)
showed pro-tumorigenic behavior. The data from Pello
et al. demonstrated that the activation of tumor-associated
macrophage requires the transcription factor c-MYC,
and c-MYC controls the induction of about 45 % of
genes associated with M2 macrophage activation, such
as SCARB1, ALOX15 and MRC1; whereas myc inhibition
prevents the activation of M2 macrophages and their pro-
tumorigenic behavior [105]. Myc also regulates metastasis
of malignancies [106]. It not only promotes EMT of can-
cer cells through activation of SNAIL and HMGA2, but
also facilitates the invasion and migration of cancer cells
via directly activating transcription of a bunch of invasion
or migration-promoting factors, such as LGALS1, OPN
and RhoA [106]. It has been demonstrated that myc is es-
sential for the vasculogenesis and angiogenesis during
tumor progression [107]. The mechanisms of myc mas-
terly regulating angiogenesis was associated with that myc
directly activates the expression of VEGF, a potent angio-
genesis inducer, but indirectly inhibits the expression of
angiogenesis inhibitors thrombospondin-1 through in-
duction of miR-17-92 cluster [108]. Additionally, myc
induced genome instability has been noticed recently
[101]. Myc was revealed to affect genome amplifications,
nucleus organization [101] and impair DNA damage
repairs [109, 110].
It has been revealed that c-myc can directly bind the
promoter of LIN28B and thus elevate the production of
LIN28B and consequently inhibit the generation of let-7
family of miRNAs upon activation of MAPK signaling
Fig. 4 The LIN28/let-7/MYC feedbacks loop and the crosstalk of hallmarks of cancer
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[26]. Interestingly, over-expression of LIN28 was shown
to elevate the expression of myc via down-regulation of
let-7, which targets the MYC gene. These results sug-
gested a complicated feedback loop consisting of
LIN28B, let-7 and MYC. Since myc is one of the target
genes of let-7, let-7-mediated inhibition of myc thus in-
hibits the crosstalk of hallmarks of cancers; LIN28A/
LIN28B, of course, has the opposite effect. The LIN28/
let-7/MYC feedbacks loop and the crosstalk of hallmarks
of cancer has been shown in Fig. 4.
The expression of LIN28/let-7/MYC feedbacks is regu-
lated by many signaling pathways and oncogenes. When
Wnt signals are absent, the cytoplasm β-catenin is
degraded by APC/GSK3β/Axin complex, while Wnt li-
gands bind to Frizzled receptor, cytoplasm β-catenin is
accumulated and translocates to the nucleus where β-
catenin promotes the transcription of myc gene [111].
This implies that β-catenin may also indirectly up-
regulate LIN28 expression via elevating myc level. Re-
cently, it has been reported that β-catenin can directly
promote the transcription of LIN28B [29]. Growth fac-
tors binding to their receptors result in the activation of
RAS, which either activates ERK (MAPK signaling) or
PI3K/AKT signaling. ERK directly activates the tran-
scription of myc, while AKT indirectly promotes the
expression of myc gene via activating β-catenin activity
[111], which suggests that RAS may regulate the expres-
sion of LIN28. Indeed, RAS has been found to inhibit
the generation of let-7 by upregulating the expression of
LIN28 via MAPK activated myc expression [26]. AKT
also activates the NF-κB signaling via activating IKK,
and NF-κB has been reported to directly promotes the
transcription of LIN28B and thus inhibits the generation
of let-7 s [27]. Interestingly, RAS and AKT are the direct
targets of let-7 s respectively [60, 112]. These results
suggested that there is a complicated crosstalk between
RAS, PI3K/AKT, NF-κB, LIN28A/LIN28B and let-7 loop.
The crosstalk between these oncogenes and LIN28A/
LIN28B and let-7 loop is summarized in Fig. 5.
Conclusion and perspective
In summary, in a variety of cancer types, let-7 is most
frequently down-regulated, while LIN28A/LIN28B is most
frequently up-regulated, and the aberrant expression of
one component of theLIN28A/LIN28B and let-7 loop due
to transcriptional and/or post-transcriptional level dysreg-
ulation in human malignant tumors would result in the al-
teration of the other one. High levels of LIN28A/LIN28B
and low levels of let-7 contribute to the development of
human malignances through promoting cellular prolifera-
tion, cell death resistance, angiogenesis, metastasis, me-
tabolism reprogramming, tumor-associated inflammation,
genome instability, acquiring immortality and evading im-
mune destruction of cancer cells. The many established
studies suggest that the LIN28A/LIN28B and let-7 loop is
a master regulator of cancer development and would be a
valuable target for future cancer therapeutic strategies.
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